BioCentury | Mar 18, 2020
Regulation

FDA’s clinical trial guidance stresses patient safety, studies’ integrity amid outbreak

...study is to enroll elderly patients, and Iveric cited caution for their safety. Meanwhile, Switzerland’s Addex...
BioCentury | Mar 4, 2020
Management Tracks

Karp, Ghosh depart Biogen; plus Exelixis, Senti, Applied Therapeutics, Oncopeptides, Acacia and more

...a newly created position. Sehgal was SVP of regulatory affairs and conformance at Celularity Inc. Addex...
...& Co. Inc. (NYSE:MRK) from March 2007 to December 2018. BioCentury Staff Applied Therapeutics Inc. twoXAR Inc. Rafael Pharmaceuticals Inc. Addex...
BioCentury | Oct 3, 2018
Distillery Therapeutics

Neurology

...Therapeutics S.A. have foliglurax, a small molecule mGluR4 PAM, in Phase II testing for PD. Addex...
BioCentury | Apr 3, 2018
Distillery Therapeutics

Neurology

...Next steps could include testing PAMs of CHRM4 in additional animal models of Rett syndrome. Addex...
BioCentury | Mar 30, 2018
Financial News

Addex raises $43M

...premium to Addex's closing price of CHF2.98 on Feb. 14, before it proposed the offering. Addex...
...Group were the placement agents on the financing. Addex Therapeutics Ltd. (SIX:ADXN), Geneva, Switzerland Jennie Walters Dipraglurant-IR (ADX48621) Addex...
BioCentury | Mar 29, 2018
Financial News

Addex raises $43M

...premium to Addex's closing price of CHF2.98 on Feb. 14, before it proposed the offering. Addex...
...Group were the placement agents on the financing. Addex gained CHF0.07 to CHF2.87 Thursday. Jennie Walters Dipraglurant-IR (ADX48621) Addex...
BioCentury | Feb 23, 2018
Financial News

Addex proposes CHF40M private placement

...Neurology company Addex Therapeutics Ltd. (SIX:ADXN) proposed on Feb. 15 to raise up to CHF40 million...
...shares at CHF3.43. The company will ask shareholders to vote on the offering in March. Addex...
...mGluR5; GRM5) has completed Phase IIb testing for PD-LID. Addex Therapeutics Ltd. (SIX:ADXN), Geneva, Switzerland Sandi Wong dipraglurant-ER Addex...
BioCentury | Feb 17, 2018
Financial News

Addex proposes CHF40M private placement

...shares at CHF3.43. The company will ask shareholders to vote on the offering in March. Addex...
...of metabotropic glutamate receptor subtype 5 (mGluR5; GRM5) has completed Phase IIb testing for PD-LID. Addex...
...which announced the offering after market close Thursday, was off CHF0.06 to CHF3.17 on Friday. Sandi Wong dipraglurant-ER Addex...
BioCentury | Sep 18, 2017
Company News

Management tracks: Kamada, Vertex, Addex, Achillion

...accounting officer, will serve as interim CFO while the company seeks a replacement. Neurology company Addex...
BioCentury | Sep 14, 2017
Translation in Brief

Tracking TrkB agonists

...to point out the artifacts associated with the Western blot reagents. At least two companies, Addex...
...Therapeutics Ltd. (SIX:ADXN) and MimeTech S.r.l. , still have active TrkB small molecule agonist programs. Addex...
...directly with binding by a macromolecule ligand like BDNF. Robert Lutjens, head of discovery at Addex...
Items per page:
1 - 10 of 228
BioCentury | Mar 18, 2020
Regulation

FDA’s clinical trial guidance stresses patient safety, studies’ integrity amid outbreak

...study is to enroll elderly patients, and Iveric cited caution for their safety. Meanwhile, Switzerland’s Addex...
BioCentury | Mar 4, 2020
Management Tracks

Karp, Ghosh depart Biogen; plus Exelixis, Senti, Applied Therapeutics, Oncopeptides, Acacia and more

...a newly created position. Sehgal was SVP of regulatory affairs and conformance at Celularity Inc. Addex...
...& Co. Inc. (NYSE:MRK) from March 2007 to December 2018. BioCentury Staff Applied Therapeutics Inc. twoXAR Inc. Rafael Pharmaceuticals Inc. Addex...
BioCentury | Oct 3, 2018
Distillery Therapeutics

Neurology

...Therapeutics S.A. have foliglurax, a small molecule mGluR4 PAM, in Phase II testing for PD. Addex...
BioCentury | Apr 3, 2018
Distillery Therapeutics

Neurology

...Next steps could include testing PAMs of CHRM4 in additional animal models of Rett syndrome. Addex...
BioCentury | Mar 30, 2018
Financial News

Addex raises $43M

...premium to Addex's closing price of CHF2.98 on Feb. 14, before it proposed the offering. Addex...
...Group were the placement agents on the financing. Addex Therapeutics Ltd. (SIX:ADXN), Geneva, Switzerland Jennie Walters Dipraglurant-IR (ADX48621) Addex...
BioCentury | Mar 29, 2018
Financial News

Addex raises $43M

...premium to Addex's closing price of CHF2.98 on Feb. 14, before it proposed the offering. Addex...
...Group were the placement agents on the financing. Addex gained CHF0.07 to CHF2.87 Thursday. Jennie Walters Dipraglurant-IR (ADX48621) Addex...
BioCentury | Feb 23, 2018
Financial News

Addex proposes CHF40M private placement

...Neurology company Addex Therapeutics Ltd. (SIX:ADXN) proposed on Feb. 15 to raise up to CHF40 million...
...shares at CHF3.43. The company will ask shareholders to vote on the offering in March. Addex...
...mGluR5; GRM5) has completed Phase IIb testing for PD-LID. Addex Therapeutics Ltd. (SIX:ADXN), Geneva, Switzerland Sandi Wong dipraglurant-ER Addex...
BioCentury | Feb 17, 2018
Financial News

Addex proposes CHF40M private placement

...shares at CHF3.43. The company will ask shareholders to vote on the offering in March. Addex...
...of metabotropic glutamate receptor subtype 5 (mGluR5; GRM5) has completed Phase IIb testing for PD-LID. Addex...
...which announced the offering after market close Thursday, was off CHF0.06 to CHF3.17 on Friday. Sandi Wong dipraglurant-ER Addex...
BioCentury | Sep 18, 2017
Company News

Management tracks: Kamada, Vertex, Addex, Achillion

...accounting officer, will serve as interim CFO while the company seeks a replacement. Neurology company Addex...
BioCentury | Sep 14, 2017
Translation in Brief

Tracking TrkB agonists

...to point out the artifacts associated with the Western blot reagents. At least two companies, Addex...
...Therapeutics Ltd. (SIX:ADXN) and MimeTech S.r.l. , still have active TrkB small molecule agonist programs. Addex...
...directly with binding by a macromolecule ligand like BDNF. Robert Lutjens, head of discovery at Addex...
Items per page:
1 - 10 of 228